华润三九及旗下昆药集团获评2023年度“上市公司董办最佳实践案例”
近日,由(you)中国上市(shi)公司协会(简称“中上协”)主办的“2023上市(shi)公司董(dong)办最(zui)佳实践”创建(jian)活(huo)动结(jie)果正式发布,华润三(san)九及旗下昆(kun)药(yao)集团均(jun)获评“上市(shi)公司董(dong)办最(zui)佳实践案例”。
中(zhong)上协(xie)通过本活动对上市公(gong)(gong)(gong)司董事(shi)会办(ban)(ban)公(gong)(gong)(gong)室(shi)履职情(qing)况(kuang)进行(xing)评价,评价体系涵盖(gai)了上市公(gong)(gong)(gong)司董事(shi)会办(ban)(ban)公(gong)(gong)(gong)室(shi)工作所涉及(ji)的信息披露管理(li)事(shi)务、公(gong)(gong)(gong)司治(zhi)理(li)机制(zhi)建设(she)、投资者关系管理(li)事(shi)务、相关制(zhi)度的制(zhi)定(ding)和修订、监(jian)督培训等指(zhi)标。本次获(huo)评,体现(xian)出华润三(san)九和昆药集(ji)团在合规治(zhi)理(li)经营(ying)、高效运作管理(li)和充分回应市场关切等方面得到中(zhong)上协(xie)的高度肯定(ding)。
华润(run)三(san)九(jiu)积(ji)极为股(gu)东创造价值(zhi),履行公(gong)(gong)司责(ze)任,持续(xu)(xu)(xu)提升公(gong)(gong)司治(zhi)(zhi)理(li)(li)及投(tou)资(zi)(zi)者关(guan)系管(guan)理(li)(li)水平(ping)。在(zai)治(zhi)(zhi)理(li)(li)层面(mian)(mian),公(gong)(gong)司持续(xu)(xu)(xu)完(wan)善权(quan)责(ze)清晰(xi)、协(xie)调运转(zhuan)高效的(de)法人治(zhi)(zhi)理(li)(li)结构,推(tui)动(dong)(dong)三(san)会规范运作(zuo),保障董监事切(qie)实(shi)履职,持续(xu)(xu)(xu)提升公(gong)(gong)司科(ke)学治(zhi)(zhi)理(li)(li)水平(ping);在(zai)信息披(pi)露层面(mian)(mian),公(gong)(gong)司确保信息披(pi)露流程的(de)与(yu)(yu)时俱进、高效透明,并积(ji)极披(pi)露ESG实(shi)践情况(kuang),回应各利(li)(li)益相关(guan)方(fang)的(de)期望与(yu)(yu)关(guan)注(zhu),切(qie)实(shi)维(wei)护投(tou)资(zi)(zi)者的(de)知情权(quan);在(zai)投(tou)资(zi)(zi)者关(guan)系管(guan)理(li)(li)层面(mian)(mian),公(gong)(gong)司建立多(duo)渠道(dao)、多(duo)角度、多(duo)层面(mian)(mian)的(de)投(tou)资(zi)(zi)者互动(dong)(dong)机制(zhi)(zhi),以便投(tou)资(zi)(zi)者全方(fang)位、立体化地(di)了解(jie)公(gong)(gong)司信息;在(zai)资(zi)(zi)本(ben)运作(zuo)层面(mian)(mian),公(gong)(gong)司密切(qie)关(guan)注(zhu)资(zi)(zi)本(ben)市场动(dong)(dong)向(xiang),顺利(li)(li)完(wan)成并购昆药集(ji)团的(de)重大资(zi)(zi)产重组事项,实(shi)施首次限(xian)制(zhi)(zhi)性(xing)股(gu)权(quan)激励计划(hua),致力于不断提升公(gong)(gong)司价值(zhi)和股(gu)东回报(bao)。
未来,华(hua)润三九及昆药集(ji)团(tuan)将(jiang)在夯实规(gui)范运作(zuo)的基础(chu)上,持续优化(hua)公司(si)治理,不断(duan)强化(hua)透明、合规(gui)的信息披露和创新高效的投(tou)资者(zhe)关系(xi)管理,为(wei)(wei)股东创造长(zhang)期(qi)稳(wen)定(ding)的回报,为(wei)(wei)推动企业可持续、高质(zhi)量发展蓄势赋能。